Landscape → Infectious Disease

Hepatitis C

324 clinical trials

16 active

324 total (since 2015)

Phase 1 Active

47 total

Phase 2 Active

107 total

Phase 3 Active

107 total

Phase 4 Active

90 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

Atea Pharmaceuticals, Inc. 2 3 1

Gilead 0 37 2

AbbVie 0 34 2

Merck 0 11 4

Sunshine Lake Pharma Co., Ltd. 0 9 0

Bristol-Myers Squibb 0 3 3

Ascletis Pharmaceuticals Co., Ltd. 0 6 0

Johnson & Johnson 0 3 1

Alios Biopharma Inc. 0 2 1

NCT07037277 RECRUITING

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Atea Pharmaceuticals, Inc. n=880

NCT06868264 ACTIVE NOT RECRUITING

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Atea Pharmaceuticals, Inc. n=880

NCT02890719 WITHDRAWN

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Fundacion Clinic per a la Recerca Biomédica

NCT05395416 COMPLETED

Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Sunshine Lake Pharma Co., Ltd. n=514

NCT04903626 COMPLETED

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

AbbVie n=286

NCT04885855 COMPLETED

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Muhammad Radzi Abu Hassan n=322

NCT03099135 TERMINATED

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Janssen Research & Development, LLC n=24

NCT05465434 COMPLETED

Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.

Tanta University n=50

NCT03801707 COMPLETED

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

Ohio State University n=54

NCT03067129 COMPLETED

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

AbbVie n=129

NCT02596880 COMPLETED

Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics

Tehran University of Medical Sciences n=100

NCT03496233 COMPLETED

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo n=75

NCT05616598 COMPLETED

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Benha University n=200

NCT02660905 COMPLETED

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

Ottawa Hospital Research Institute n=25

NCT02634008 COMPLETED

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Kirby Institute n=83

NCT02939989 COMPLETED

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

AbbVie n=33

NCT04112303 COMPLETED

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Gilead Sciences n=37

NCT04382937 COMPLETED

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

PharmaEssentia n=222

NCT02625909 COMPLETED

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

Kirby Institute n=222

NCT04211909 COMPLETED

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Gilead Sciences n=87

NCT02486406 COMPLETED

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

AbbVie n=64

NCT02455167 TERMINATED

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

University of Colorado, Denver n=9

NCT02555943 COMPLETED

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Humanity and Health Research Centre n=23

NCT02640157 COMPLETED

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

AbbVie n=506

NCT02582632 COMPLETED

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

AbbVie n=166

NCT02966795 COMPLETED

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

AbbVie n=84

NCT02640482 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

AbbVie n=304

NCT02723084 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

AbbVie n=136

NCT02707952 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

AbbVie n=295

NCT02642432 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

AbbVie n=146

NCT02738138 COMPLETED

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

AbbVie n=153

NCT02604017 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

AbbVie n=703

NCT02692703 COMPLETED

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

AbbVie n=100

NCT02636595 COMPLETED

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

AbbVie n=121

NCT03480932 COMPLETED

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

Johns Hopkins Bloomberg School of Public Health n=150

NCT03883698 COMPLETED

Safety of Sofosbuvir in People With Advanced Kidney Failure

Sanjay Gandhi Postgraduate Institute of Medical Sciences n=30

NCT03020082 COMPLETED

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Ascletis Pharmaceuticals Co., Ltd. n=141

NCT04155515 COMPLETED

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. n=370

NCT02825212 COMPLETED

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

Icahn School of Medicine at Mount Sinai n=10

NCT03578640 COMPLETED

Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

King Fahad Medical City n=30

NCT02973503 COMPLETED

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

University Hospital, Clermont-Ferrand n=117

NCT02441283 COMPLETED

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

AbbVie n=384

NCT04546802 WITHDRAWN

HepATocellular Cancer Hcv Therapy Study

Bayside Health

NCT03362814 COMPLETED

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Ascletis Pharmaceuticals Co., Ltd. n=425

NCT03089944 COMPLETED

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

AbbVie n=343

NCT04387526 COMPLETED

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Beni-Suef University n=946

NCT03487107 COMPLETED

Phase 3 Study of Yimitasvir Phosphate Capsules

Sunshine Lake Pharma Co., Ltd. n=362

NCT03219216 COMPLETED

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

AbbVie n=100

NCT02613871 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Gilead Sciences n=111

NCT03092375 COMPLETED

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

University of Florida n=177

NCT03222583 COMPLETED

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

AbbVie n=546

NCT03117569 COMPLETED

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Kirby Institute n=380

NCT02609659 COMPLETED

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

AbbVie n=105

NCT03235349 COMPLETED

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

AbbVie n=160

NCT03212521 COMPLETED

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

AbbVie n=230

NCT02600325 COMPLETED

Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

Erasmus Medical Center n=80

NCT03995485 COMPLETED

KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C

Kawin Technology Share-holding Co., Ltd. n=371

NCT03118843 COMPLETED

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Gilead Sciences n=31

NCT03074331 COMPLETED

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Gilead Sciences n=130

NCT02607735 COMPLETED

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

Gilead Sciences n=416

NCT02639247 COMPLETED

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Gilead Sciences n=333

NCT02607800 COMPLETED

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Gilead Sciences n=943

NCT02639338 COMPLETED

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Gilead Sciences n=220

NCT03069365 COMPLETED

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

AbbVie n=101

NCT02996682 COMPLETED

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Gilead Sciences n=102

NCT03369327 COMPLETED

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

Tehran University of Medical Sciences n=232

NCT02251990 COMPLETED

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Merck Sharp & Dohme LLC n=489

NCT03004625 COMPLETED

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Kaohsiung Medical University Chung-Ho Memorial Hospital n=70

NCT03186365 COMPLETED

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Kaohsiung Medical University Chung-Ho Memorial Hospital n=82

NCT02671500 COMPLETED

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Gilead Sciences n=375

NCT02722837 COMPLETED

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Gilead Sciences n=119

NCT02346721 COMPLETED

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Gilead Sciences n=111

NCT02738333 COMPLETED

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Gilead Sciences n=239

NCT02480712 COMPLETED

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Gilead Sciences n=107

NCT02600351 TERMINATED

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Gilead Sciences n=87

NCT02487030 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Gilead Sciences n=255

NCT02472886 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Gilead Sciences n=153

NCT02822794 COMPLETED

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Gilead Sciences n=117

NCT02707601 COMPLETED

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Gilead Sciences n=150

NCT02597166 COMPLETED

Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection

University Health Network, Toronto n=14

NCT02517528 COMPLETED

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

AbbVie n=104

NCT02358044 COMPLETED

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Merck Sharp & Dohme LLC n=257

NCT03490097 COMPLETED

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Ain Shams University n=100

NCT02785666 COMPLETED

Swiss HCVree Trial

University of Zurich n=150

NCT03080415 COMPLETED

Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir

Yassin Abdelghaffar Charity Center for Liver Disease and Research n=40

NCT02673489 COMPLETED

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Bristol-Myers Squibb n=106

NCT02705534 COMPLETED

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

Tehran University of Medical Sciences n=50

NCT02473211 COMPLETED

SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients

Humanity and Health Research Centre n=106

NCT02576314 COMPLETED

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Humanity and Health Research Centre n=48

NCT03186313 COMPLETED

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

Egyptian Liver Hospital n=72

NCT02504099 TERMINATED

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

AbbVie n=3

NCT02487199 COMPLETED

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

AbbVie n=18

NCT02517515 COMPLETED

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

AbbVie n=650

NCT02651194 COMPLETED

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

AbbVie n=104

NCT02442284 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

AbbVie n=99

NCT02476617 COMPLETED

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

AbbVie n=25

NCT02446717 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

AbbVie n=141

NCT02442271 COMPLETED

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

AbbVie n=222

NCT01890200 WITHDRAWN

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

TCM Biotech International Corp.

NCT02496078 COMPLETED

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Bristol-Myers Squibb n=207

NCT02319031 COMPLETED

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Bristol-Myers Squibb n=53

NCT02319200 TERMINATED

Primary Prevention Hepatocellular Carcinoma by Metformin

Assistance Publique - Hôpitaux de Paris n=11

NCT02399345 COMPLETED

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

AbbVie n=10

NCT02806362 WITHDRAWN

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

AbbVie

NCT02250807 COMPLETED

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Janssen R&D Ireland n=40

NCT02483156 COMPLETED

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Egyptian Liver Hospital n=80

NCT02478229 TERMINATED

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

University Health Network, Toronto n=1

NCT07040319 NOT YET RECRUITING

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05832229 RECRUITING

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT03222531 ACTIVE NOT RECRUITING

Expanding the Pool in Orthotopic Heart Transplantation

Mary E. Keebler, MD

NCT03809533 ACTIVE NOT RECRUITING

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

Amit D Tevar, MD

NCT05597800 NOT YET RECRUITING

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Universita di Verona

NCT05904470 COMPLETED

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Atea Pharmaceuticals, Inc.

NCT05014087 TERMINATED

Digoxin In Treatment of Alcohol Associated Hepatitis

Yale University

NCT03819322 COMPLETED

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

Fernanda P Silveira, MD, MS

NCT02940496 COMPLETED

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

NCT02583685 COMPLETED

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Humanity and Health Research Centre

NCT04710641 COMPLETED

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Mina Alpha Limited

NCT03620474 COMPLETED

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Kiminori Kimura, MD

NCT04042740 COMPLETED

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02613403 TERMINATED

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

Merck Sharp & Dohme LLC

NCT03903185 COMPLETED

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Ain Shams University

NCT02340962 COMPLETED

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

TaiGen Biotechnology Co., Ltd.

NCT03118674 COMPLETED

Harvoni Treatment Porphyria Cutanea Tarda

Wake Forest University Health Sciences

NCT03379506 COMPLETED

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

Merck Sharp & Dohme LLC

NCT02836925 COMPLETED

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Fondazione Italiana Linfomi - ETS

NCT04246723 COMPLETED

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

R-Pharm

NCT04309734 WITHDRAWN

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Atea Pharmaceuticals, Inc.

NCT02971033 TERMINATED

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

VA Office of Research and Development

NCT04596475 COMPLETED

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

University of California, San Diego

NCT02745535 COMPLETED

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

University of Maryland, Baltimore

NCT03236506 COMPLETED

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

University of Dundee

NCT02194998 TERMINATED

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05091008 COMPLETED

Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children

Mansoura University Children Hospital

NCT03523871 COMPLETED

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

NYU Langone Health

NCT03818308 COMPLETED

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Hannover Medical School

NCT03501550 COMPLETED

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Cocrystal Pharma, Inc.

NCT03487848 TERMINATED

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Bristol-Myers Squibb

NCT02541409 COMPLETED

Directly Observed Therapy for HCV in Chennai, India

Johns Hopkins Bloomberg School of Public Health

NCT03593447 COMPLETED

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

NCT02956629 TERMINATED

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Merck Sharp & Dohme LLC

NCT03820258 TERMINATED

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Gilead Sciences

NCT03020095 COMPLETED

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Ascletis Pharmaceuticals Co., Ltd.

NCT03022981 COMPLETED

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Gilead Sciences

NCT04202952 COMPLETED

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects

Sunshine Lake Pharma Co., Ltd.

NCT04391985 COMPLETED

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Beni-Suef University

NCT04387539 COMPLETED

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Beni-Suef University

NCT04385407 COMPLETED

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Beni-Suef University

NCT04378608 COMPLETED

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Beni-Suef University

NCT04382339 COMPLETED

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

Beni-Suef University

NCT03794258 WITHDRAWN

Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

Humanity & Health Medical Group Limited

NCT04019717 COMPLETED

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Atea Pharmaceuticals, Inc.

NCT02468648 COMPLETED

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT03458481 COMPLETED

Phase 2 Study of Yimitasvir Phosphate Capsules

Sunshine Lake Pharma Co., Ltd.

NCT02378935 COMPLETED

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Gilead Sciences

NCT03036852 COMPLETED

Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Gilead Sciences

NCT02378961 COMPLETED

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Gilead Sciences

NCT02994056 COMPLETED

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Gilead Sciences

NCT02868242 COMPLETED

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Gilead Sciences

NCT03036839 COMPLETED

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Gilead Sciences

NCT02886624 COMPLETED

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

NCT02765490 COMPLETED

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Janssen Research & Development, LLC

NCT02993250 COMPLETED

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Janssen Pharmaceutical K.K.

NCT02601573 COMPLETED

Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

Merck Sharp & Dohme LLC

NCT02332720 COMPLETED

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Merck Sharp & Dohme LLC

NCT02332707 COMPLETED

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Merck Sharp & Dohme LLC

NCT02569710 COMPLETED

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Alios Biopharma Inc.

NCT02759315 TERMINATED

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Merck Sharp & Dohme LLC

NCT03119025 COMPLETED

Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection

Russian Academy of Medical Sciences

NCT02421211 COMPLETED

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Janssen Sciences Ireland UC

NCT03282474 COMPLETED

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Hannover Medical School

NCT02336139 COMPLETED

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

Kirby Institute

NCT02536313 COMPLETED

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Gilead Sciences

NCT02728206 COMPLETED

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Gilead Sciences

NCT03485846 COMPLETED

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

R-Pharm

NCT02781558 COMPLETED

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Gilead Sciences

NCT02301936 COMPLETED

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Gilead Sciences

NCT02350569 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Gilead Sciences

NCT02457611 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Gilead Sciences

NCT02413593 COMPLETED

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Gilead Sciences

NCT02781571 COMPLETED

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Gilead Sciences

NCT03020004 COMPLETED

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Ascletis Pharmaceuticals Co., Ltd.

NCT02605304 TERMINATED

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02306070 WITHDRAWN

Improving Fibrosis Outcomes With Metformin

Ottawa Hospital Research Institute

NCT03416491 COMPLETED

Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C

Kawin Technology Share-holding Co., Ltd.

NCT02356562 COMPLETED

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

AbbVie

NCT02405013 COMPLETED

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

ANRS, Emerging Infectious Diseases

NCT02493855 COMPLETED

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

AbbVie

NCT02716428 COMPLETED

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Trek Therapeutics, PBC

NCT02647632 COMPLETED

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

ANRS, Emerging Infectious Diseases

NCT02932293 WITHDRAWN

Triple Combination DAAs for Treating HCV GT1b Subjects

Humanity and Health Research Centre

NCT02268864 COMPLETED

A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

Janssen-Cilag International NV

NCT02349048 COMPLETED

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Janssen Research & Development, LLC

NCT02593162 COMPLETED

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Trek Therapeutics, PBC

NCT02480387 COMPLETED

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Peter J. Ruane, M.D., Inc.

NCT02470858 COMPLETED

Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Humanity and Health Research Centre

NCT02556086 WITHDRAWN

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Bristol-Myers Squibb

NCT02551861 WITHDRAWN

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Bristol-Myers Squibb

NCT02772003 ACTIVE NOT RECRUITING

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

National Cancer Institute (NCI)

NCT07237282 NOT YET RECRUITING

A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

University of Alberta

NCT04382404 COMPLETED

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Catherine Anne Chappell

NCT02143401 COMPLETED

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

NCT03688061 COMPLETED

Class II Invariant Chain HCV Vaccine Study

University of Oxford

NCT03377478 COMPLETED

Expanding the Pool in Lung Transplantation

Pablo Sanchez

NCT04774107 COMPLETED

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

PharmaEssentia

NCT02760758 COMPLETED

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

Cocrystal Pharma, Inc.

NCT02565888 COMPLETED

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Radboud University Medical Center

NCT02565862 COMPLETED

A Drug-drug Interaction Study Between Daclatasvir and Metformin

Radboud University Medical Center

NCT04232514 COMPLETED

Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects

Sunshine Lake Pharma Co., Ltd.

NCT03513393 COMPLETED

Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.

Radboud University Medical Center

NCT03817619 COMPLETED

Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet

Radboud University Medical Center

NCT02533427 COMPLETED

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

Gilead Sciences

NCT03674125 COMPLETED

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

GeneOne Life Science, Inc.

NCT02397707 COMPLETED

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Gilead Sciences

NCT02402452 COMPLETED

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Gilead Sciences

NCT03811678 COMPLETED

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects

Sunshine Lake Pharma Co., Ltd.

NCT04201275 COMPLETED

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

Sunshine Lake Pharma Co., Ltd.

NCT03673696 COMPLETED

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

Sunshine Lake Pharma Co., Ltd.

NCT03903081 COMPLETED

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects

Sunshine Lake Pharma Co., Ltd.

NCT02683005 COMPLETED

Study of Hepatitis C Treatment During Pregnancy

Catherine Chappell

NCT03219957 COMPLETED

Study of AT-527 in Healthy and HCV-Infected Subjects

Atea Pharmaceuticals, Inc.

NCT02512562 COMPLETED

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Alios Biopharma Inc.

NCT02392494 COMPLETED

Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

Merck Sharp & Dohme LLC

NCT02661126 COMPLETED

Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

Merck Sharp & Dohme LLC

NCT02461563 COMPLETED

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Merck Sharp & Dohme LLC

NCT03686722 COMPLETED

Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin

Mohamed Raslan

NCT02568332 COMPLETED

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

University of Oxford

NCT02666352 COMPLETED

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

Merck Sharp & Dohme LLC

NCT03588923 COMPLETED

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

Nanjing Sanhome Pharmaceutical, Co., Ltd.

NCT03430830 COMPLETED

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Ascletis Pharmaceuticals Co., Ltd.

NCT03341988 COMPLETED

Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

Assiut University

NCT03288636 COMPLETED

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Ascletis Pharmaceuticals Co., Ltd.

NCT03253471 TERMINATED

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Alios Biopharma Inc.

NCT02652377 COMPLETED

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Enanta Pharmaceuticals, Inc

NCT06953479 RECRUITING

Implementing Low-Barrier HCV Treatment in a Jail Setting

Lifespan

NCT05140941 RECRUITING

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

Catherine Anne Chappell

NCT03520660 ACTIVE NOT RECRUITING

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT04508907 ACTIVE NOT RECRUITING

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Mayo Clinic

NCT07098481 NOT YET RECRUITING

Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy

ANRS, Emerging Infectious Diseases

NCT02460133 ACTIVE NOT RECRUITING

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Nova Scotia Health Authority

NCT06306300 RECRUITING

Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)

Oswaldo Cruz Foundation

NCT03949764 COMPLETED

The Kentucky Viral Hepatitis Treatment Study

Jennifer Havens

NCT03987503 COMPLETED

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

University of California, San Francisco

NCT05582681 TERMINATED

HCV Test and Treat Utilizing Simplified HCV Patient Education

Weill Medical College of Cornell University

NCT04515797 TERMINATED

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Massachusetts General Hospital

NCT02881762 COMPLETED

Maraviroc Efficacy for Hepatitis C

University of Maryland, Baltimore

NCT02902120 COMPLETED

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

University of Maryland, Baltimore

NCT04575896 COMPLETED

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Johns Hopkins University

NCT02759861 COMPLETED

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

University of Nebraska

NCT05264558 COMPLETED

Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%

Macfarlane Burnet Institute for Medical Research and Public Health Ltd

NCT03537196 COMPLETED

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)

ANRS, Emerging Infectious Diseases

NCT02992457 COMPLETED

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Tanta University

NCT03003338 TERMINATED

MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV

Hannover Medical School

NCT03823911 COMPLETED

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

University of Maryland, Baltimore

NCT03057847 COMPLETED

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

Elizabeth Krans, MD

NCT03797066 TERMINATED

ATTIC - Access To Treat in the Community

King's College Hospital NHS Trust

NCT03625687 TERMINATED

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

Massachusetts General Hospital

NCT04653818 COMPLETED

HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

Alexandria University

NCT04695769 COMPLETED

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

Helwan University

NCT04320290 WITHDRAWN

HCV + to HCV - Kidney Transplant

Massachusetts General Hospital

NCT03208127 TERMINATED

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Massachusetts General Hospital

NCT03208244 TERMINATED

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

Massachusetts General Hospital

NCT04614142 WITHDRAWN

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Massachusetts General Hospital

NCT02938013 COMPLETED

deLIVER: Direct Acting Antiviral Effects on the Liver

Johns Hopkins University

NCT03512210 COMPLETED

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT03781726 COMPLETED

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Raymond Chung

NCT03365635 COMPLETED

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

University of Pennsylvania

NCT02786537 COMPLETED

Study of Oral Treatments for Hepatitis C

University of Florida

NCT02946034 COMPLETED

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

Massachusetts General Hospital

NCT03627299 COMPLETED

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

Johns Hopkins University

NCT02964091 COMPLETED

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

Partners in Health

NCT03235154 COMPLETED

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

Community Research Initiative of New England

NCT04235049 WITHDRAWN

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

University of Maryland, Baltimore

NCT03723824 TERMINATED

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Taichung Veterans General Hospital

NCT03619837 COMPLETED

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

University of California, San Francisco

NCT03126370 COMPLETED

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

University of Colorado, Denver

NCT02533934 COMPLETED

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

University of California, San Francisco

NCT02461745 COMPLETED

Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

Kaiser Permanente

NCT03389061 WITHDRAWN

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet

Radboud University Medical Center

NCT03093415 COMPLETED

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

Oregon Health and Science University

NCT02609893 COMPLETED

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs

Phillip Coffin, MD, MIA

NCT04457050 COMPLETED

Effect of Hepatitis C Clearance on Insulin Resistance

Alexandria University

NCT03111108 COMPLETED

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Merck Sharp & Dohme LLC

NCT02858180 COMPLETED

Hepatitis C Virus(HCV) Heart and Lung Study

Duke University

NCT03381859 WITHDRAWN

Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4

University of Maryland, Baltimore

NCT03420300 COMPLETED

EBR/GZR for HCV-1b Patients Receiving Hemodialysis

National Taiwan University Hospital

NCT02940691 TERMINATED

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

Kirby Institute

NCT02429583 TERMINATED

Effects of Persistent Innate Immune Activation on Vaccine Efficacy

Rockefeller University

NCT03791814 WITHDRAWN

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

Albert Einstein Healthcare Network

NCT03313414 WITHDRAWN

HCV Post-Exposure Prophylaxis for Health Care Workers

Massachusetts General Hospital

NCT03499639 COMPLETED

Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

Assiut University

NCT02895958 TERMINATED

The Dublin Zepatier Study

Mater Misericordiae University Hospital

NCT04177043 COMPLETED

Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages

Egyptian Liver Hospital

NCT03063879 COMPLETED

Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

Tehran University of Medical Sciences

NCT03207399 TERMINATED

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Duke University

NCT03221582 TERMINATED

Impact of Hepatitis C Therapy and Bone Health

Dallas VA Medical Center

NCT02347345 COMPLETED

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Rockefeller University

NCT02734173 COMPLETED

Pilot HCV Direct Acting Antiviral Therapy and Metabolism

Ottawa Hospital Research Institute

NCT03050905 COMPLETED

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B

HaEmek Medical Center, Israel

NCT02498015 COMPLETED

A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection

Kirby Institute

NCT03623568 WITHDRAWN

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Raymond T. Chung, MD

NCT03144635 COMPLETED

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

Kyushu University

NCT03961828 COMPLETED

Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

Tanta University

NCT02631772 COMPLETED

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Medical University of South Carolina

NCT02304159 COMPLETED

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Tarek I. Hassanein, M.D., FACP, FAG, AGAF

NCT03200184 COMPLETED

Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

Tehran University of Medical Sciences

NCT03093740 WITHDRAWN

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Massachusetts General Hospital

NCT03026023 WITHDRAWN

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Raymond T. Chung, MD

NCT03098121 COMPLETED

Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

Taoyuan General Hospital

NCT03710252 COMPLETED

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

American Research Corporation

NCT03032666 COMPLETED

Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial

Ala'a Sharara

NCT02804386 COMPLETED

Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon

PharmEvo Pvt Ltd

NCT02781649 COMPLETED

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

Johns Hopkins University

NCT03585101 WITHDRAWN

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

University of California, Los Angeles

NCT02580474 COMPLETED

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Myeong Jun Song

NCT03105349 WITHDRAWN

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

Fundacion SEIMC-GESIDA

NCT02482077 COMPLETED

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

Humanity and Health Research Centre

NCT03250910 COMPLETED

Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

National Taiwan University Hospital

NCT03143998 WITHDRAWN

Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

Merck Sharp & Dohme LLC

NCT02624063 COMPLETED

Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

Federal University of São Paulo

NCT02768961 COMPLETED

Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)

Instituto de Investigación Marqués de Valdecilla

NCT03069001 COMPLETED

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

Ain Shams University

NCT02480686 COMPLETED

Neutrino Regimen for Treatment-experienced HCV GT1 Patients

Humanity and Health Research Centre

NCT02292966 WITHDRAWN

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism

Kirby Institute

Data: ClinicalTrials.gov